Take2 Health

Take2 Health is a Hong Kong-based healthcare and diagnostics company focused on early cancer detection, particularly nasopharyngeal cancer. Founded in 2019 and built around inventions commercialized from researchers at The Chinese University of Hong Kong, the company markets blood-based screening and monitoring tests that use next-generation sequencing to analyze Epstein-Barr virus DNA signals associated with nasopharyngeal cancer. Its lead commercial products include Take2 Prophecy for early nasopharyngeal cancer screening and Take2 Clarity for recurrence-risk monitoring after treatment. Beyond standalone tests, the company also offers cancer-screening packages, health-check services, and a digital booking/member platform for consumers and provider partners. Its commercial footprint appears centered on Hong Kong with expansion efforts into other Asian markets including Shenzhen, Taiwan, and the Philippines.